Clinical Trial To Evaluate Safety And Efficacy Of US-APR2020 In Subjects With Chronic Kidney Disease Stage IV (CKD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04913272 |
|
Recruitment Status :
Recruiting
First Posted : June 4, 2021
Last Update Posted : June 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Kidney Disease stage4 | Drug: US-APR2020 Drug: Placebo | Phase 2 |
Kidney diseases are a global public health problem that affects over 200 million people worldwide. It is estimated that about 30 million adults in the United States have Chronic Kidney Disease (CKD) and most are undiagnosed. In addition, CKD represents the ninth leading cause of death in the United States. Kidney diseases also represent great socio-economical cost worldwide. In the United States, treating Medicare beneficiaries with CKD costed over $79 billion, and treating people with End Stage Kidney Disease (ESKD) costed an additional $35 billion in 2016. To date, there is no cure for CKD.
The most important CKD risk factors in adults include diabetes and high blood pressure. Other risk factors include heart disease, obesity, a family history of CKD, past damage to the kidneys, and old age. Having CKD increases the chances of also having heart disease and stroke.
CKD is a condition characterized by a gradual loss of kidney function over time. Depending on the kidney function measured with glomerular filtration rate (GFR) CKD can be classified into several stages (I, II, III, IV and V). CKD Stage V, also known as End Stage Kidney Disease (ESKD), is a very advanced stage of kidney disease where the kidneys have lost nearly all ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. Treatment may slow the decline in kidney function and failure. However, not everyone with CKD develops ESKD, and in some cases ESKD develops even with treatment.
CKD is accompanied by altered pathogenic gut bacteria, inflammation, and accumulation of uremic toxins in the blood. These blood uremic toxins can diffuse passively into the bowel. Scientific research has shown that probiotic bacteria could metabolize various uremic toxins such as urea, uric acid, and creatinine. In addition, by supplementing the gut microbiome with probiotic bacteria, it is possible to metabolize the nitrogenous waste products and other toxins which diffuse into the gut, and thus lower levels of inflammation and blood uremic toxins.
US-APR2020 is a live biotherapeutic (LBT) intended to restore the gut microbiome to improve the removal of uremic toxins in the bowel in CKD patients. The aim of this Phase 2 study is to evaluate the safety and efficacy of the US-APR2020 in the management of patients with CKD Stage IV.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 630 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter clinical trial to evaluate the safety and efficacy of US-APR2020 in patients with CKD Stage IV. Following Screening and Enrollment, patients will be Randomized to either Group US-APR2020 or Placebo. In Group US-APR2020, the drug US-APR2020 will be administered orally at 2 capsules per day (one capsule in the morning and one capsule in the evening, after meals, for a total daily dose of 90 Billion CFUs) for six months. Subjects will be followed for 6 months. Patients in Placebo Group will be administered Placebo tablets in similar routine. |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Double-blind |
| Primary Purpose: | Treatment |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of US-APR2020 In Subjects With Chronic Kidney Disease Stage IV |
| Actual Study Start Date : | June 24, 2021 |
| Estimated Primary Completion Date : | September 2022 |
| Estimated Study Completion Date : | December 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: US-APR2020
Patients in this group will be administered US-APR2020 orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals, (for a total daily dose of 90 Billion CFUs).
|
Drug: US-APR2020
US-APR2020 capsules 45 billion CFUs of the LBT. |
|
Placebo Comparator: Placebo
Patients in this group will be administered placebo orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals.
|
Drug: Placebo
Placebo |
- Evaluate incidences of Treatment-Emergent Adverse Events following US-APR2020 administration in patients with Chronic Kidney disease (CKD) Stage IV as a measure of safety. [ Time Frame: six months ]Presence of adverse events in less than 10% of the study population, as a measure of safety
- Evaluate the change of eGFR as per NKF-USFDA guidelines following US-APR2020 administration in patients with Chronic Kidney disease (CKD) Stage IV as a measure of clinical efficacy. [ Time Frame: six months ]Arresting the change of Estimated glomerular filtration rate (eGFR) as per National Kidney Foundation- US Food and Drug Administration (NKF-USFDA )guidelines in the group treated with US-APR2020 as compared to the placebo, as a measure of efficacy.
- Evaluate changes in basic blood uremic metabolic markers [ Time Frame: six months ]
Change in any of the basic blood uremic metabolic markers in the group treated with US-APR2020 as compared to the placebo:
- Blood Urea Nitrogen (BUN)
- Uric acid
- Serum creatinine
- Urea/creatinine ratio
- Micro albumin urea
- Evaluate changes in complete blood count and hematology parameters [ Time Frame: six months ]
Change in any of the complete blood count (CBC) and hematology parameters in the group treated with US-APR2020 as compared to the placebo:
- Red blood cells
- White blood cells
- Platelets
- Hemoglobin (Hgb)
- Hematocrit (Hct) Ferritin
- Evaluate changes in C-Reactive Protein (CRP) levels [ Time Frame: six months ]Change in C-Reactive Protein (CRP) levels in the group treated with US-APR2020 as compared to the placebo
- Evaluate change in quality of life (QOL)- SF36 QOL questionnaire [ Time Frame: six months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults between the ages of 18-80 years
- CKD Stage IV (eGFR = 15-29 mL/min) with declining kidney function for a period > 6 months
- Serum Creatinine > 2.0 mg/dL
- Adherence to low protein diet (LPD) of 0.6-0.8 g/kg/day based on subject response and on advisory
Exclusion Criteria:
- Those on probiotic supplements in the past 3 months
- Pregnancy, breast feeding or females of child-bearing potential who are unwilling to use a reliable form of contraception.
- Immunosuppressant medications therapy specific to immune mediated renal diseases
- HIV/AIDs
- Underweight (BMI ≤ 18.5)
- Subject with an infection that requires oral antibiotic administration at the time of randomization or close to that visit.
- Those with gastrointestinal disease (irritable bowel syndrome or anal fissures or anal fistulas or perianal abscesses or perianal infections or diverticular diseases or colitis or colon polyps) at the time of screening and randomization, or within 6 months prior to the randomization visit (Visit 2)
- Those with internal prosthesis including orthopedics, neurosurgery, heart valves, vascular stents ˂ 2 years post -surgery procedure. Those with Prosthesis > 2 years should not be excluded.
- Those with biological/tissue grafts or prosthesis or implant
- Those on anticoagulant medicines, including Vit K antagonists (e.g., warfarin, coumadin) or the new class of oral anti-coagulants approved by FDA in the last 10 years
- Those on peritoneal dialysis
- Those with acute kidney injury
- Those with mental conditions or medically debilitating disease/disorder other than CKD, which, in the judgment of the investigator, would interfere with or serve as a contraindication to adherence to the study protocol or affect the ability to give informed consent or affect overall prognosis of the patient.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04913272
| Contact: Mukesh Kumar, PhD | 2407504893 | mkumar@fdamap.com |
| United States, Maryland | |
| Jadedstone Clinical Research | Recruiting |
| Silver Spring, Maryland, United States, 20904 | |
| Contact: Mukesh Kumar 240-750-4893 mkumar@fdamap.com | |
| United States, Michigan | |
| Kidney Michigan | Recruiting |
| Saginaw, Michigan, United States, 48604 | |
| Contact: Mukesh Kumar 240-750-4893 mkumar@fdamap.com | |
| United States, South Carolina | |
| South Carolina Clinical Research | Recruiting |
| Orangeburg, South Carolina, United States, 29118 | |
| Contact: Mukesh Kumar 240-750-4893 mkumar@fdamap.com | |
| United States, Texas | |
| Almeda Medical Clinic | Recruiting |
| Houston, Texas, United States, 77058 | |
| Contact: Mukesh Kumar 240-750-4893 mkumar@fdamap.com | |
| United States, Virginia | |
| Mendez Center for Clinical Research | Recruiting |
| Woodbridge, Virginia, United States, 22192 | |
| Contact: Mukesh Kumar 240-750-4893 mkumar@fdamap.com | |
| Responsible Party: | Kibow Pharma |
| ClinicalTrials.gov Identifier: | NCT04913272 |
| Other Study ID Numbers: |
US-APR2020-01 |
| First Posted: | June 4, 2021 Key Record Dates |
| Last Update Posted: | June 3, 2022 |
| Last Verified: | March 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Kidney Diseases Renal Insufficiency, Chronic Urologic Diseases Renal Insufficiency |